{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T05:16:39Z","timestamp":1788498999242,"version":"build-2803163510"},"reference-count":45,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["52272273"],"award-info":[{"award-number":["52272273"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"award":["52272273"],"award-info":[{"award-number":["52272273"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005046","name":"Natural Science Foundation of Heilongjiang Province of China","doi-asserted-by":"crossref","award":["PL2024H153"],"award-info":[{"award-number":["PL2024H153"]}],"id":[{"id":"10.13039\/501100005046","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100010722","name":"Graduate Practice Innovation Project of Harbin Medical University","doi-asserted-by":"publisher","award":["YJSCX202574HYD"],"award-info":[{"award-number":["YJSCX202574HYD"]}],"id":[{"id":"10.13039\/100010722","id-type":"DOI","asserted-by":"publisher"}]},{"award":["YJSCX202574HYD"],"award-info":[{"award-number":["YJSCX202574HYD"]}],"id":[{"id":"https:\/\/ror.org\/05jscf583","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Objectives: Platinum-based neoadjuvant therapy can improve pathological response in triple-negative breast cancer (TNBC), but severe hematotoxicity may compromise treatment delivery. This study developed and validated a multitask learning framework to jointly predict pathological complete response (pCR) and severe hematotoxicity and to support benefit\u2013hematotoxicity stratification. Methods: This multicenter retrospective study included 2060 consecutive patients with TNBC receiving platinum-based neoadjuvant therapy at three institutions. Patients were assigned to a training cohort (n = 1406), an internal validation cohort (n = 351), or an external validation cohort (n = 303). A multitask TabNet (MT-TabNet) model was developed using pretreatment clinical, pathological, imaging, laboratory, electrocardiographic, and planned treatment exposure variables to jointly estimate pCR and severe hematotoxicity. Model performance was evaluated using discrimination, calibration, decision curve analysis, and interpretability analyses. The predicted probabilities were further integrated into a utility-based framework for benefit\u2013hematotoxicity stratification. Results: Overall, 639 patients (31.0%) achieved pCR, and 651 (31.6%) developed severe hematotoxicity. MT-TabNet achieved AUCs of 0.874, 0.842, and 0.819 for pCR prediction and 0.859, 0.846, and 0.818 for severe hematotoxicity prediction in the training, internal validation, and external validation cohorts, respectively. The model showed generally acceptable calibration and clinical net benefit. pCR prediction was predominantly associated with tumor-related characteristics, whereas severe hematotoxicity prediction was more strongly associated with planned treatment exposure and host-related laboratory indicators. Utility-based stratification showed progressively higher pCR rates and lower severe hematotoxicity rates from the low- to high-benefit groups across all three cohorts. Survival differed significantly among benefit groups for both progression-free survival (PFS) and overall survival (OS) in the training and internal validation cohorts; in the external validation cohort, OS differed significantly, whereas PFS showed a similar but nonsignificant trend. Conclusions: MT-TabNet enabled joint estimation of pCR and severe hematotoxicity in patients with TNBC receiving platinum-based neoadjuvant therapy. The utility-based framework integrated efficacy and toxicity predictions into clinically interpretable benefit\u2013hematotoxicity stratification and warrants further prospective evaluation for individualized risk assessment and toxicity monitoring.<\/jats:p>","DOI":"10.3390\/cancers18172842","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T14:35:29Z","timestamp":1788359729000},"page":"2842","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Benefit\u2013Hematotoxicity Stratification in Patients with Triple-Negative Breast Cancer Receiving Platinum-Based Neoadjuvant Therapy: A Multitask Deep Learning Study"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2001-7056","authenticated-orcid":false,"given":"Hao","family":"Sun","sequence":"first","affiliation":[{"name":"Department of Breast Surgery, The Sixth Affiliated Hospital of Harbin Medical University, No. 998 Aiying Street, Songbei District, Harbin 150023, China"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"writing-original-draft","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"given":"Xinglu","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of PET\/CT Center, Harbin Medical University Cancer Hospital, No. 150 Haping Road, Nangang District, Harbin 150081, China"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"writing-original-draft","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"given":"Jian","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, The Sixth Affiliated Hospital of Harbin Medical University, No. 998 Aiying Street, Songbei District, Harbin 150023, China"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"data-curation","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"}]},{"given":"Yujie","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, The Sixth Affiliated Hospital of Harbin Medical University, No. 998 Aiying Street, Songbei District, Harbin 150023, China"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"data-curation","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"}]},{"given":"Bao","family":"Deng","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, The Sixth Affiliated Hospital of Harbin Medical University, No. 998 Aiying Street, Songbei District, Harbin 150023, China"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"investigation","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"}]},{"given":"Ziqi","family":"Guo","sequence":"additional","affiliation":[{"name":"The Second Affiliated Hospital of Harbin Medical University, No. 246 Xuefu Road, Nangang District, Harbin 150001, China"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"investigation","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"}]},{"given":"Tong","family":"Su","sequence":"additional","affiliation":[{"name":"Department of Ultrasound, The Sixth Affiliated Hospital of Harbin Medical University, No. 998 Aiying Street, Songbei District, Harbin 150023, China"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"methodology","vocabulary":"credit"},{"role":"supervision","vocabulary":"credit"}]},{"given":"Binbin","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Ultrasound, The Sixth Affiliated Hospital of Harbin Medical University, No. 998 Aiying Street, Songbei District, Harbin 150023, China"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"methodology","vocabulary":"credit"},{"role":"supervision","vocabulary":"credit"}]},{"given":"Lei","family":"Zhong","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, The Sixth Affiliated Hospital of Harbin Medical University, No. 998 Aiying Street, Songbei District, Harbin 150023, China"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"resources","vocabulary":"credit"},{"role":"project-administration","vocabulary":"credit"},{"role":"funding-acquisition","vocabulary":"credit"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"232","DOI":"10.37349\/etat.2024.00215","article-title":"Early-stage triple negative breast cancer: The therapeutic role of immunotherapy and the prognostic value of pathological complete response","volume":"5","author":"Perrone","year":"2024","journal-title":"Explor. Target. Antitumor Ther."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1007\/s12032-024-02456-9","article-title":"The treatment landscape of triple-negative breast cancer","volume":"41","author":"Hu","year":"2024","journal-title":"Med. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1200\/JCO.20.03399","article-title":"Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline","volume":"39","author":"Korde","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"5550","DOI":"10.1245\/s10434-026-19121-2","article-title":"Surgical Outcomes After Neoadjuvant Pembrolizumab Plus Chemotherapy for Triple-Negative Breast Cancer: Results from the Randomized, Placebo-Controlled Phase 3 KEYNOTE-522 Study","volume":"33","author":"Kuemmel","year":"2026","journal-title":"Ann. Surg. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S1470-2045(21)00589-1","article-title":"Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: A multicentre pooled analysis of 5161 patients","volume":"23","author":"Yau","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJMoa2112651","article-title":"Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer","volume":"386","author":"Schmid","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1056\/NEJMoa2409932","article-title":"Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer","volume":"391","author":"Schmid","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"103712","DOI":"10.1016\/j.breast.2024.103712","article-title":"Platinum chemotherapy for early triple-negative breast cancer","volume":"75","author":"Mason","year":"2024","journal-title":"Breast"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"101096","DOI":"10.1016\/j.currproblcancer.2024.101096","article-title":"Platinum dose in neoadjuvant therapy for triple-negative breast cancer: A systematic review and network meta-analysis","volume":"50","author":"Petrelli","year":"2024","journal-title":"Curr. Probl. Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1200\/JCO.21.01506","article-title":"CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer","volume":"40","author":"Shepherd","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e44740","DOI":"10.1097\/MD.0000000000044740","article-title":"Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: An updated systematic review and meta-analysis","volume":"104","author":"Wu","year":"2025","journal-title":"Medicine"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"102427","DOI":"10.1016\/j.ctrv.2022.102427","article-title":"Chemotherapy-induced neutropenia and emerging agents for prevention and treatment: A review","volume":"109","author":"Blayney","year":"2022","journal-title":"Cancer Treat. Rev."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s12672-023-00616-3","article-title":"Chemotherapy-induced thrombocytopenia: Literature review","volume":"14","author":"Gao","year":"2023","journal-title":"Discov. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Buchrits, S., Itzhaki, O., Avni, T., Raanani, P., and Gafter-Gvili, A. (2022). Intravenous Iron Supplementation for the Treatment of Chemotherapy-Induced Anemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J. Clin. Med., 11.","DOI":"10.3390\/jcm11144156"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1080\/14737140.2021.1941891","article-title":"Prophylaxis and treatment strategies for optimizing chemotherapy relative dose intensity","volume":"21","author":"Shayne","year":"2021","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1016\/j.ejso.2021.01.025","article-title":"Optimal timing of surgery following breast cancer neoadjuvant chemotherapy: A systematic review and meta-analysis","volume":"47","author":"Cullinane","year":"2021","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"102198","DOI":"10.1016\/j.esmoop.2023.102198","article-title":"Discontinuation rate and serious adverse events of chemoimmunotherapy as neoadjuvant treatment for triple-negative breast cancer: A systematic review and meta-analysis","volume":"8","author":"Rizzo","year":"2023","journal-title":"ESMO Open"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.3324\/haematol.2021.279512","article-title":"Treatment of chemotherapy-induced thrombocytopenia in patients with non-hematologic malignancies","volume":"107","author":"Kuter","year":"2022","journal-title":"Haematologica"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1200\/CCI.21.00046","article-title":"Prediction of Neutropenic Events in Chemotherapy Patients: A Machine Learning Approach","volume":"5","author":"Wiberg","year":"2021","journal-title":"JCO Clin. Cancer Inform."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/s41598-023-27518-2","article-title":"Prediction of pathologic complete response to neoadjuvant systemic therapy in triple negative breast cancer using deep learning on multiparametric MRI","volume":"13","author":"Zhou","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s13058-023-01726-0","article-title":"PROACTING: Predicting pathological complete response to neoadjuvant chemotherapy in breast cancer from routine diagnostic histopathology biopsies with deep learning","volume":"25","author":"Aswolinskiy","year":"2023","journal-title":"Breast Cancer Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"102066","DOI":"10.1016\/j.ejon.2021.102066","article-title":"Development of a prediction models for chemotherapy-induced adverse drug reactions: A retrospective observational study using electronic health records","volume":"56","author":"On","year":"2022","journal-title":"Eur. J. Oncol. Nurs."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Yasmeen, R., Khan, L., and Choi, A. (2025). Heart disease prediction using hybrid TabNet architecture with stacked ensemble learning. Front. Physiol., 16.","DOI":"10.3389\/fphys.2025.1665128"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1109\/JBHI.2023.3327951","article-title":"GenHPF: General Healthcare Predictive Framework for Multi-task Multi-source Learning","volume":"28","author":"Hur","year":"2024","journal-title":"IEEE J. BioMed. Health Inform."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"106644","DOI":"10.1016\/j.neunet.2024.106644","article-title":"Multi-task heterogeneous graph learning on electronic health records","volume":"180","author":"Chan","year":"2024","journal-title":"Neural Netw."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"109237","DOI":"10.1016\/j.compbiomed.2024.109237","article-title":"M3T-LM: A multi-modal multi-task learning model for jointly predicting patient length of stay and mortality","volume":"183","author":"Chen","year":"2024","journal-title":"Comput. Biol. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1109\/JBHI.2021.3064696","article-title":"Deep Semisupervised Multitask Learning Model and Its Interpretability for Survival Analysis","volume":"25","author":"Chi","year":"2021","journal-title":"IEEE J. BioMed. Health Inform."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1016\/j.csbj.2021.07.003","article-title":"Machine learning in the prediction of cancer therapy","volume":"19","author":"Rafique","year":"2021","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"936","DOI":"10.7150\/jca.52439","article-title":"Novel biomarkers and prediction model for the pathological complete response to neoadjuvant treatment of triple-negative breast cancer","volume":"12","author":"Han","year":"2021","journal-title":"J. Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Cui, H., Zhao, D., Han, P., Zhang, X., Fan, W., Zuo, X., Wang, P., Hu, N., Kong, H., and Peng, F. (2021). Predicting Pathological Complete Response After Neoadjuvant Chemotherapy in Advanced Breast Cancer by Ultrasound and Clinicopathological Features Using a Nomogram. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.718531"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"391","DOI":"10.2217\/nnm-2020-0458","article-title":"Retrospective comparisons of nanoparticle albumin-bound paclitaxel and docetaxel neoadjuvant regimens for breast cancer","volume":"16","author":"Li","year":"2021","journal-title":"Nanomedicine"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"626","DOI":"10.3348\/kjr.2022.0974","article-title":"Prediction of Tumor Progression During Neoadjuvant Chemotherapy and Survival Outcome in Patients With Triple-Negative Breast Cancer","volume":"24","author":"Yoen","year":"2023","journal-title":"Korean J. Radiol."},{"key":"ref_33","first-page":"2347","article-title":"Acute toxicity and tolerability of anthracycline-based chemotherapy regimens in older versus younger patients with breast cancer: Real-world data","volume":"29","author":"Monteiro","year":"2021","journal-title":"Support. Care Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1200\/JCO.20.02063","article-title":"Development and Validation of a Risk Tool for Predicting Severe Toxicity in Older Adults Receiving Chemotherapy for Early-Stage Breast Cancer","volume":"39","author":"Magnuson","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1002\/cncr.32718","article-title":"Associations between nutritional factors and chemotherapy toxicity in older adults with solid tumors","volume":"126","author":"Dotan","year":"2020","journal-title":"Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e1516","DOI":"10.1634\/theoncologist.2019-0701","article-title":"Predicting Chemotherapy Toxicity in Older Patients with Cancer: A Multicenter Prospective Study","volume":"25","author":"Feliu","year":"2020","journal-title":"Oncologist"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1080\/17474086.2021.1924053","article-title":"Clinical challenges and promising therapies for chemotherapy-induced thrombocytopenia","volume":"14","author":"Soff","year":"2021","journal-title":"Expert Rev. Hematol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"103821","DOI":"10.1016\/j.breast.2024.103821","article-title":"Chemotherapy in older patients with early breast cancer","volume":"78","author":"Schmidt","year":"2024","journal-title":"Breast"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"9919269","DOI":"10.1155\/2023\/9919269","article-title":"Interpretability of Clinical Decision Support Systems Based on Artificial Intelligence from Technological and Medical Perspective: A Systematic Review","volume":"2023","author":"Xu","year":"2023","journal-title":"J. Healthc. Eng."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Msaouel, P., Lee, J., and Thall, P.F. (2021). Making Patient-Specific Treatment Decisions Using Prognostic Variables and Utilities of Clinical Outcomes. Cancers, 13.","DOI":"10.3390\/cancers13112741"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1007\/s10147-024-02541-z","article-title":"Therapeutic use of granulocyte colony-stimulating factor (G-CSF) in patients with febrile neutropenia: A comprehensive systematic review for clinical practice guidelines for the use of G-CSF 2022 from the Japan Society of Clinical Oncology","volume":"29","author":"Tsuchihashi","year":"2024","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Chen, W., Liu, Y., Li, L., and Zeng, X. (2023). Efficacy and safety of thrombopoietin receptor agonists in solid tumors with chemotherapy-induced thrombocytopenia: A meta-analysis. BMC Pharmacol. Toxicol., 24.","DOI":"10.1186\/s40360-023-00707-5"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Liu, Z., Li, J., Zhao, F., Ren, D., Li, Z., Chen, Y., Huang, S., Liu, Z., Zhao, Y., and Wang, M. (2024). Long-term survival after neoadjuvant therapy for triple-negative breast cancer under different treatment regimens: A systematic review and network meta-analysis. BMC Cancer, 24.","DOI":"10.1186\/s12885-024-12222-9"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"8060","DOI":"10.1245\/s10434-022-12300-x","article-title":"Residual Cancer Burden Class Associated with Survival Outcomes in Women with Different Phenotypic Subtypes of Breast Cancer After Neoadjuvant Chemotherapy","volume":"29","author":"Elder","year":"2022","journal-title":"Ann. Surg. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1097\/CCO.0000000000000893","article-title":"Postneoadjuvant treatment for triple-negative breast cancer","volume":"34","author":"Trapani","year":"2022","journal-title":"Curr. Opin. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/17\/2842\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T04:27:53Z","timestamp":1788496073000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/17\/2842"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,2]]},"references-count":45,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["cancers18172842"],"URL":"https:\/\/doi.org\/10.3390\/cancers18172842","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,2]]}}}